GX-19 is being developed by a consortium led by Genexine, a Korean biotech company.Current Status: This vaccine is under a phase I/IIa trial in South Korea.Mode of Action: GX-19 is a DNA vaccine that is designed to make antigens by first inserting nucleic acids into the body. The antigen then produces induced immune responses against the novel coronavirus. Next Milestone: The phase I part of the trial was started on June 17, 2020 and is expected to be completed by September 2020.